- Report
- March 2025
- 1048 Pages
Global
From €4562EUR$4,799USD£3,833GBP
- Report
- November 2024
- 600 Pages
Global
From €3137EUR$3,300USD£2,636GBP
- Report
- October 2024
- 181 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 189 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 138 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- January 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- December 2022
- 363 Pages
Global
From €4562EUR$4,799USD£3,833GBP
- Report
- February 2024
- 75 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- February 2024
- 250 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- November 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2023
- 450 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- March 2024
- 207 Pages
Global
From €1898EUR$1,997USD£1,595GBP
- Report
- September 2022
Global
€4990EUR$5,623USD£4,339GBP
- Report
- June 2022
- 844 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- November 2021
- 747 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- December 2023
- 248 Pages
Global
From €3394EUR$3,570USD£2,851GBP

The Neoantigen market is a subset of the Genomics market that focuses on the identification and development of neoantigens for use in cancer immunotherapy. Neoantigens are proteins that are produced by tumor cells and are recognized by the immune system as foreign, triggering an immune response. By targeting these neoantigens, cancer immunotherapy can be used to treat cancer. Companies in the Neoantigen market are focused on developing technologies to identify and develop neoantigens for use in cancer immunotherapy.
Companies in the Neoantigen market include Adaptive Biotechnologies, I-Mab, Neoantigen Therapeutics, NeoVax, and OncoImmune. Show Less Read more